|
| | | | | | | | | | | |
| Name | Indication | Class | Approved | Economics | IP | Admin | | Price | 61.9 | |
| Jakafi (ruxolitinib) | Myelofibrosis, GvHD | JAK1/2 | 11/16/2011 | NVS Ex-US | 2026-2028 | Oral | | Shares | 226 | Q123 |
| Monjuvi/Minjuvi (tafasitamab) | DLBCL | CD19 | | MOR | mab | IV | | MC | 13989.4 | |
| Olumiant (baricitinib) | Alopecia Areata | JAK | 5/31/2018 | LLY | | Oral | | Cash | 3126.2459999999996 | Q322 |
| Tabrecta (capmatinib) | NSCLC | c-Met | 5/6/2020 | NVS | | Oral | | Debt | 0 | Q322 |
| Iclusig (ponatinib) | CML | Bcr-Abl | | TAK US | | Oral | | EV | 10863.154 | |
| Pemaryze (pemigatinib) | cholangiocarcinoma | FGFR1/2/3 | 4/17/2020 | 1 | | | | | | |
| Zynyz (retifanlimab) | anal cancer | PD-1 | 3/22/2023 | MGNX | | IV | | | | |
| Opzelura (ruxolitinib) | Vitiligo | JAK1/2 | 7/18/2022 | 100%? | | Cream | | CEO: Herve Hoppenot | | |
| | | | Phase | | | | | HemOnc Clinical Development: Lance Leopold | | |
| parsaclisib | AIHA, FL, MF | PI3Kdelta | III | 1 | | Oral | | CMO: Steven Stein | | |
| INCB57643 | Myelofibrosis | BET | II | 1 | | Oral | | Group VP, Oncology: Peter Langmuir | | |
| INCB00928 | Myelofibrosis | ALK2 | II | 1 | | Oral | | | | |
| povorcitinib (INCB54707) | HS, Vitiligo, PN | JAK1 | II | 1 | | Oral | | | | |
| itacitinib | GvHD | JAK1 | | 1 | | Oral | | | | |
| axatilimab | GvHD | CSF-1R | II | SNDX | | IV | | | | |
| INCB86550 | Oncology | PD-L1 | I | 1 | peripheral neuropathy - deprioritized/cancelled | | | | | |
| INCB99318 | Oncology | PD-L1 | I | 1 | | | | | | |
| INCB99280 | Oncology | PD-L1 | I | 1 | | | | | | |
| INCB123667 | Oncology | CDK2 | I | 1 | | | | | | |
| INCB81776 | Oncology | AXL/MER | | | | | | | | |
| auremolimab | Vitiligo | IL-15betaR | IND | 1 | | | | | | |
| epacadostat | Oncology | IDO1 | | | | | | | | |
| INCB106385 | Oncology | A2A/A2B | | | | | | | | |
| INCAGN2385 | Oncology | LAG-3 mab | | AGEN | | | | | | |
| INCAGN1949 | Oncology | OX40 mab | | AGEN | | | | | | |
| INCAGN2390 | Oncology | TIM-3 mab | | AGEN | | | | | | |
| INCA00186 | Oncology | CD73 mab | | AGEN | | | | | | |
| INCA32459 | Oncology | LAG-3/PD-1 | | Merus | | | | | | |
| INCAGN1876 | Oncology | GITR mab | | AGEN | | | | | | |
| CK0804 | Myelofibrosis | CB-Tregs | | Cellenkos | | | | | | |
| | | | | | | | | | | |
| | | | | | 7/18/22: Opzelura approve for vitiligo. | | | | | |
| | | | | | 7/12/22: Q2 earnings date. | | | | | |
| | | | | | 6/13/22: Olumiant approved for alopecia areata. | | | | | |
| | | | | | 6/13/22: CT collaboration with PFE TTI-622 and Monjuvi | | | | | |
| | | | | | 5/26/22: EHA preview | | | | | |
| | | | | | 5/24/22: investor conference | | | | | |
| | | | | | 5/20/22: CHMP recommends Olumiant for AA | | | | | |
| | | | | | 5/11/22: Olumiant approved for COVID-19 | | | | | |
| | | | | | 5/5/22: EC approves Jakavi for post-steroid GvHD | | | | | |
| | | | | | 5/4/22: investor conference | | | | | |
| | | | | | 5/3/22: Q122 results. | | | | | |
| | | | | | | | | | | |
| | | | | | 9/2008: INCB18424 Psoriasis Phase II data presented. | | | | | |
| | | | | | October 24-29 2008: ACR presentation of 424 in second dose group. | | | | | |
| | | | | | YE08: 424 results in HRPC/Multiple Myeloma | | | | | |
| | | | | | YE08: INCB7839 combination with Herceptin Phase II results. | | | | | |
| | | | | | YE08: 424 results in myelofibrosis at ASH. | | | | | |
| | | | | | Early 2009: INCB19602 Phase II proof-of-concept data in diabetes. | | | | | |
| | | | | | Nov 2009: partner ex-US rights for '424 in cancer with NVS, and ww rights to INCB28060 in all indications (w right to co-develop & co-promote in US) | | | | | |
| | | | | | Dec 2009: partner ww rights for INCB28050 with LLY for inflam and autoimmune diseases | | | | | |
| | | | | | Jan 2010: initiate European Ph3 trial of '424 | | | | | |
| | | | | | July 2010: INCY opts to co-develop INCB28050 in RA (and retains option to co-promote in US) | | | | | |
| | | | | | Oct 2010: LLY initiatesPh2b of INCB28050 in RA | | | | | |
| | | | | | Oct 2010: Initiate Ph3 trial of '424 in polycythemia vera | | | | | |
| | | | | | Nov 10, 2010: Ph2a data of INCB28050 in RA presented ACR | | | | | |
| | | | | | Dec 20, 2010: Positive topline data reported for COMFORT-1 of '424 in myelofibrosis, NDA to be filed in Q211 | | | | | |
| | | | | | H111: submit NDA for ruxolitinib in MF | | | | | |
| | | | | | H111: results from COMFORT-1 Ph3 US trial in MF | | | | | |
| | | | | | late 2011: launch ruxolitinib in MF | | | | | |
| | | | | | 2011: NVS to present results from COMFORT-II Ph3 EU trial and submit MAA for MF | | | | | |
| | | | | | late 2011: complete enrollment in joint global Ph3 RESPONSE trial in PV | | | | | |